Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
Provided By GlobeNewswire
Last update: Oct 30, 2025
GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025.
Read more at globenewswire.com
